A system dynamics model of serum prostate-specific antigen screening for prostate cancer

Anton Palma, David W. Lounsbury, Nicolas F. Schlecht, Ilir Agalliu

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Since 2012, US guidelines have recommended against prostate-specific antigen (PSA) screening for prostate cancer. However, evidence of screening benefit from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening trial and the European Randomized Study of Screening for Prostate Cancer has been inconsistent, due partly to differences in noncompliance and contamination. Using system dynamics modeling, we replicated the PLCO trial and extrapolated follow-up to 20 years. We then simulated 3 scenarios correcting for contamination in the PLCO control arm using Surveillance, Epidemiology, and End Results (SEER) incidence and survival data collected prior to the PSA screening era (scenario 1), SEER data collected during the PLCO trial period (1993-2001) (scenario 2), and data from the European trial's control arm (1991-2005) (scenario 3). In all scenarios, noncompliance was corrected using incidence and survival rates for men with screen-detected cancer in the PLCO screening arm. Scenarios 1 and 3 showed a benefit of PSA screening, with relative risks of 0.62 (95% confidence interval: 0.53, 0.72) and 0.70 (95% confidence interval: 0.59, 0.83) for cancer-specific mortality after 20 years, respectively. In scenario 2, however, there was no benefit of screening. This simulation showed that after correcting for noncompliance and contamination, there is potential benefit of PSA screening in reducing prostate cancer mortality. It also demonstrates the utility of system dynamics modeling for synthesizing epidemiologic evidence to inform public policy.

Original languageEnglish (US)
Pages (from-to)227-236
Number of pages10
JournalAmerican Journal of Epidemiology
Volume183
Issue number3
DOIs
StatePublished - Feb 1 2016

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Prostate
Serum
Lung
Epidemiology
Confidence Intervals
Mortality
Incidence
Public Policy
Early Detection of Cancer
Ovarian Neoplasms
Colorectal Neoplasms
Lung Neoplasms
Survival Rate
Guidelines
Survival
Neoplasms

Keywords

  • cancer-specific mortality
  • policy evaluation
  • prostate cancer
  • prostate-specific antigen screening
  • system dynamics modeling

ASJC Scopus subject areas

  • Epidemiology

Cite this

A system dynamics model of serum prostate-specific antigen screening for prostate cancer. / Palma, Anton; Lounsbury, David W.; Schlecht, Nicolas F.; Agalliu, Ilir.

In: American Journal of Epidemiology, Vol. 183, No. 3, 01.02.2016, p. 227-236.

Research output: Contribution to journalArticle

@article{65a8d0e5467846eead0fa432ef09bb4d,
title = "A system dynamics model of serum prostate-specific antigen screening for prostate cancer",
abstract = "Since 2012, US guidelines have recommended against prostate-specific antigen (PSA) screening for prostate cancer. However, evidence of screening benefit from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening trial and the European Randomized Study of Screening for Prostate Cancer has been inconsistent, due partly to differences in noncompliance and contamination. Using system dynamics modeling, we replicated the PLCO trial and extrapolated follow-up to 20 years. We then simulated 3 scenarios correcting for contamination in the PLCO control arm using Surveillance, Epidemiology, and End Results (SEER) incidence and survival data collected prior to the PSA screening era (scenario 1), SEER data collected during the PLCO trial period (1993-2001) (scenario 2), and data from the European trial's control arm (1991-2005) (scenario 3). In all scenarios, noncompliance was corrected using incidence and survival rates for men with screen-detected cancer in the PLCO screening arm. Scenarios 1 and 3 showed a benefit of PSA screening, with relative risks of 0.62 (95{\%} confidence interval: 0.53, 0.72) and 0.70 (95{\%} confidence interval: 0.59, 0.83) for cancer-specific mortality after 20 years, respectively. In scenario 2, however, there was no benefit of screening. This simulation showed that after correcting for noncompliance and contamination, there is potential benefit of PSA screening in reducing prostate cancer mortality. It also demonstrates the utility of system dynamics modeling for synthesizing epidemiologic evidence to inform public policy.",
keywords = "cancer-specific mortality, policy evaluation, prostate cancer, prostate-specific antigen screening, system dynamics modeling",
author = "Anton Palma and Lounsbury, {David W.} and Schlecht, {Nicolas F.} and Ilir Agalliu",
year = "2016",
month = "2",
day = "1",
doi = "10.1093/aje/kwv262",
language = "English (US)",
volume = "183",
pages = "227--236",
journal = "American Journal of Epidemiology",
issn = "0002-9262",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - A system dynamics model of serum prostate-specific antigen screening for prostate cancer

AU - Palma, Anton

AU - Lounsbury, David W.

AU - Schlecht, Nicolas F.

AU - Agalliu, Ilir

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Since 2012, US guidelines have recommended against prostate-specific antigen (PSA) screening for prostate cancer. However, evidence of screening benefit from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening trial and the European Randomized Study of Screening for Prostate Cancer has been inconsistent, due partly to differences in noncompliance and contamination. Using system dynamics modeling, we replicated the PLCO trial and extrapolated follow-up to 20 years. We then simulated 3 scenarios correcting for contamination in the PLCO control arm using Surveillance, Epidemiology, and End Results (SEER) incidence and survival data collected prior to the PSA screening era (scenario 1), SEER data collected during the PLCO trial period (1993-2001) (scenario 2), and data from the European trial's control arm (1991-2005) (scenario 3). In all scenarios, noncompliance was corrected using incidence and survival rates for men with screen-detected cancer in the PLCO screening arm. Scenarios 1 and 3 showed a benefit of PSA screening, with relative risks of 0.62 (95% confidence interval: 0.53, 0.72) and 0.70 (95% confidence interval: 0.59, 0.83) for cancer-specific mortality after 20 years, respectively. In scenario 2, however, there was no benefit of screening. This simulation showed that after correcting for noncompliance and contamination, there is potential benefit of PSA screening in reducing prostate cancer mortality. It also demonstrates the utility of system dynamics modeling for synthesizing epidemiologic evidence to inform public policy.

AB - Since 2012, US guidelines have recommended against prostate-specific antigen (PSA) screening for prostate cancer. However, evidence of screening benefit from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening trial and the European Randomized Study of Screening for Prostate Cancer has been inconsistent, due partly to differences in noncompliance and contamination. Using system dynamics modeling, we replicated the PLCO trial and extrapolated follow-up to 20 years. We then simulated 3 scenarios correcting for contamination in the PLCO control arm using Surveillance, Epidemiology, and End Results (SEER) incidence and survival data collected prior to the PSA screening era (scenario 1), SEER data collected during the PLCO trial period (1993-2001) (scenario 2), and data from the European trial's control arm (1991-2005) (scenario 3). In all scenarios, noncompliance was corrected using incidence and survival rates for men with screen-detected cancer in the PLCO screening arm. Scenarios 1 and 3 showed a benefit of PSA screening, with relative risks of 0.62 (95% confidence interval: 0.53, 0.72) and 0.70 (95% confidence interval: 0.59, 0.83) for cancer-specific mortality after 20 years, respectively. In scenario 2, however, there was no benefit of screening. This simulation showed that after correcting for noncompliance and contamination, there is potential benefit of PSA screening in reducing prostate cancer mortality. It also demonstrates the utility of system dynamics modeling for synthesizing epidemiologic evidence to inform public policy.

KW - cancer-specific mortality

KW - policy evaluation

KW - prostate cancer

KW - prostate-specific antigen screening

KW - system dynamics modeling

UR - http://www.scopus.com/inward/record.url?scp=84962161199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962161199&partnerID=8YFLogxK

U2 - 10.1093/aje/kwv262

DO - 10.1093/aje/kwv262

M3 - Article

VL - 183

SP - 227

EP - 236

JO - American Journal of Epidemiology

JF - American Journal of Epidemiology

SN - 0002-9262

IS - 3

ER -